-
公开(公告)号:US20230233549A1
公开(公告)日:2023-07-27
申请号:US18184364
申请日:2023-03-15
Applicant: Academia Sinica
Inventor: Rong-Jie CHEIN , Pan-Chyr YANG , Chi-Huey WONG , Ming-Shiu LIN , Ting-Jen CHENG , Ting-Hung Rachel CHOU
IPC: A61K31/47 , A61P35/00 , A61K45/06 , C07D215/233
CPC classification number: A61K31/47 , A61P35/00 , A61K45/06 , C07D215/233
Abstract: Provided herein are compounds of Formula (I). The disclosure provides new compounds, compositions, and methods for treating, delaying, and/or preventing the adverse effects of proliferative diseases, such as cancers including, for example, lung cancer, breast cancer, ovarian cancer, prostate cancer, head cancer, neck cancer, head and neck cancer, or leukemia (e.g., cancer resistant to treatment by one or more microtubule-targeting agents (e.g., cancer resistant to multiple drugs associated with P-glycoprotein (P-gp) overexpression)). Provided are methods of inhibiting polymerization of a cancer cell microtubule in a subject in need thereof or a cell, tissue, or biological sample, binding β-tubulin, inhibiting microtubule assembly and, inducing apoptosis in a cancer cell resistant to multiple drugs in a tissue, biological sample, or subject. Also provided in the present disclosure are pharmaceutical compositions, kits, and methods of using the compounds for treating any of the target diseases described herein.
-
公开(公告)号:US20230302114A1
公开(公告)日:2023-09-28
申请号:US17998208
申请日:2021-05-07
Applicant: ACADEMIA SINICA
Inventor: Chi-Huey WONG , Hsin-Yu LIAO , Shih-Chi WANG , Yi-An KO , Kuo-I LIN , Che MA , Ting-Jen CHENG
IPC: A61K39/145 , C07K14/005 , A61P31/16
CPC classification number: A61K39/145 , A61P31/16 , C07K14/005 , A61K2039/575
Abstract: The present disclosure relates to a chimeric influenza virus hemagglutinin (HA) polypeptide, comprising one or more stem domain sequence, each having at least 60% homology with a stem domain consensus sequence of H1 subtype HA (H1 HA) and/or H5 subtype HA (H5 HA), fused with one or more globular head domain sequence, each having at least 60% homology with a globular head domain consensus sequence of H1 subtype HA (H1 HA) or H5 subtype HA (H5 HA).
-
公开(公告)号:US20250082744A1
公开(公告)日:2025-03-13
申请号:US18927447
申请日:2024-10-25
Applicant: ACADEMIA SINICA
Inventor: Chi-Huey WONG , Hsin-Yu LIAO , Shih-Chi WANG , Yi-An KO , Kuo-I LIN , Che MA , Ting-Jen CHENG
IPC: A61K39/145 , A61K39/00 , A61P31/16 , C07K14/005
Abstract: The present disclosure relates to a chimeric influenza virus hemagglutinin (HA) polypeptide, comprising one or more stem domain sequence, each having at least 60% homology with a stem domain consensus sequence of H1 subtype HA (H1 HA) and/or H5 subtype HA (H5 HA), fused with one or more globular head domain sequence, each having at least 60% homology with a globular head domain consensus sequence of H1 subtype HA (H1 HA) or H5 subtype HA (H5 HA).
-
公开(公告)号:US20240190866A1
公开(公告)日:2024-06-13
申请号:US18282219
申请日:2022-03-11
Applicant: Academia Sinica
Inventor: Wei-Chieh CHENG , Wei-An CHEN , Yu-Hsin CHEN , Ting-Jen CHENG , Chia-Ning SHEN , Chiao-Yun HSIEH , Pi-Fang HUNG
IPC: C07D471/04 , A61K31/437 , A61P35/00
CPC classification number: C07D471/04 , A61K31/437 , A61P35/00
Abstract: Disclosed herein are novel polyhydroxylated indolizidine and pyrrolizidine derivates and methods for using the same in the treatment of cancer. The present polyhydroxylated indolizidine and pyrrolizidine derivates has the structure of formula (I),
wherein: X is O or b and c are independently an integral of 0 or and 1; R is selected from the group consisting of H, C1-6 alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, cycloalkenyl, aralkyl, aralkenyl, aralkynyl, heteroaralkyl, heteroaralkenyl, beteroaralkynyl, heterocyclyl, alkoxy, aryloxy, and sulfonyl.-
公开(公告)号:US20250012784A1
公开(公告)日:2025-01-09
申请号:US18707599
申请日:2022-11-11
Applicant: Academia Sinica
Inventor: Chi-Huey WONG , Ching-Chuan JIANG , Shang-Cheng HUNG , Chang-Hsun HSIEH , Pi-Hui LIANG , Ting-Jen CHENG , Hwai-I YANG
IPC: G01N33/53 , A61K31/135 , A61K31/167 , A61K31/192 , A61K31/196 , A61K31/405 , A61K31/485 , A61K31/5415 , A61K31/573 , A61K31/616 , A61K31/635
Abstract: Disclosed herein is a method for identifying and treating a subject having stages III or IV osteoarthritis (OA). The method includes steps of, determining the respective levels of chondroitin-4-sulfate (C4S) and chondroitin-6-sulfate (C6S) derived from a chondroitin sulfate (CS) chain of bikunin in a biological sample of the subject; calculating a risk score (RS) of the subject with the equation: R S = 1 1 + e - f ( x ) , in which f(x)=−9.3875+0.1356×(the age of the subject)+1.1493×(the level of C4S/the level of C6S) when the subject is a female, or f(x)=−10.3389+0.1356×(the age of the subject)+1.1493×(the level of C4S/the level of C6S) when the subject is a male; and treating the subject with an analgesic, a non-steroidal anti-inflammatory drug (NSAID), a corticosteroid or a combination thereof when the determined risk score is above 0.745.
-
公开(公告)号:US20240316179A1
公开(公告)日:2024-09-26
申请号:US18662436
申请日:2024-05-13
Applicant: ACADEMIA SINICA
Inventor: Chi-Huey WONG , Hsin-Yu LIAO , Shih-Chi WANG , Yi-An KO , Kuo-I LIN , Che MA , Ting-Jen CHENG
IPC: A61K39/145 , A61K39/00 , A61P31/16 , C07K14/005
CPC classification number: A61K39/145 , A61P31/16 , C07K14/005 , A61K2039/575
Abstract: The present disclosure relates to a chimeric influenza virus hemagglutinin (HA) polypeptide, comprising one or more stem domain sequence, each having at least 60% homology with a stem domain consensus sequence of H1 subtype HA (H1 HA) and/or H5 subtype HA (H5 HA), fused with one or more globular head domain sequence, each having at least 60% homology with a globular head domain consensus sequence of H1 subtype HA (H1 HA) or H5 subtype HA (H5 HA).
-
公开(公告)号:US20240100147A1
公开(公告)日:2024-03-28
申请号:US18501578
申请日:2023-11-03
Applicant: ACADEMIA SINICA
Inventor: Chi-Huey WONG , Hsin-Yu LIAO , Shih-Chi WANG , Yi-An KO , Kuo-I LIN , Che MA , Ting-Jen CHENG
IPC: A61K39/145 , A61P31/16 , C07K14/005
CPC classification number: A61K39/145 , A61P31/16 , C07K14/005 , A61K2039/575
Abstract: The present disclosure relates to a chimeric influenza virus hemagglutinin (HA) polypeptide, comprising one or more stem domain sequence, each having at least 60% homology with a stem domain consensus sequence of H1 subtype HA (H1 HA) and/or H5 subtype HA (H5 HA), fused with one or more globular head domain sequence, each having at least 60% homology with a globular head domain consensus sequence of H1 subtype HA (H1 HA) or H5 subtype HA (H5 HA).
-
公开(公告)号:US20200330449A1
公开(公告)日:2020-10-22
申请号:US16831346
申请日:2020-03-26
Applicant: Academia Sinica
Inventor: Rong-Jie CHEIN , Pan-Chyr YANG , Chi-Huey WONG , Ming-Shiu LIN , Ting-Jen CHENG , Ting-Hung CHOU
IPC: A61K31/47 , C07D215/233 , A61K45/06 , A61P35/00
Abstract: Compounds of Formula (I) and methods for treating, delaying, and/or preventing the adverse effects of proliferative diseases, such as cancers including, for example, lung cancer, breast cancer, ovarian cancer, prostate cancer, head cancer, neck cancer, head and neck cancer, or leukemia (e.g., cancer resistant to treatment by one or more microtubule-targeting agents, e.g., cancer resistant to multiple drugs associated with P-glycoprotein (P-gp) overexpression). Methods of inhibiting polymerization of a cancer cell microtubule in a subject in need thereof or a cell, tissue, or biological sample, binding p-tubulin, inhibiting microtubule assembly and, inducing apoptosis in a cancer cell resistant to multiple drugs in a tissue, biological sample, or subject. Pharmaceutical compositions, kits, and methods of using the compounds for treating any of the target diseases described herein.
-
-
-
-
-
-
-